Economic Outlook and Accessibility of GLP-1 Medications

Serena Williams recently made headlines for her promotion of GLP-1 medications. The tennis super star is one of a growing list of celebrities turning to GLP-1s, drugs originally developed to treat patients with Type II diabetes and obesity, to help with weight loss.

Off-label use of these medications is rapidly expanding, disrupting a fitness industry built on helping people lose weight.  In May, Weight Watchers filed for bankruptcy. Questions also loom over any long-term disruptions to the human body.

Mike and Yael talk with Dr. Sandhya Chhabra (MBA’17) about the benefits, cautions, and unknowns surrounding the drug that is making headlines and changing lives. Dr. Chhabra led an endocrinology practice for 20 years and is currently a Senior Medical Advisor for Springbok Analytics.